CIDP
Clinical trials for CIDP explained in plain language.
Never miss a new study
Get alerted when new CIDP trials appear
Sign up with your email to follow new studies for CIDP, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New CIDP drug empasiprubart enters final phase of testing
Disease control Recruiting nowThis phase 3 trial tests whether empasiprubart, given by IV infusion, can help adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder that causes weakness and disability. The study will enroll 160 participants. For the first 6 months, some get the …
Matched conditions: CIDP
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New drug could replace standard infusions for nerve disorder
Disease control Recruiting nowThis study tests a new medicine called empasiprubart against the standard treatment (IVIg) for people with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disease that causes weakness and numbness. About 218 adults who have used IVIg before will receive either t…
Matched conditions: CIDP
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Blood filtering vs. antibody therapy: new hope for nerve disorder patients
Disease control Recruiting nowThis study compares two treatments for CIDP, a nerve condition that causes weakness and numbness. It involves 20 adults who did not get better with steroids. One group receives a blood-filtering procedure called immunoadsorption, and the other receives standard antibody infusions…
Matched conditions: CIDP
Phase: PHASE2 • Sponsor: University of Ulm • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New study tracks Efgartigimod's Real-World impact on CIDP patients
Disease control Recruiting nowThis study follows 200 adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are starting treatment with efgartigimod. Researchers will track changes in disability, grip strength, and quality of life over up to 2 years in everyday clinical settings. The…
Matched conditions: CIDP
Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for CIDP patients: early access to efgartigimod drug
Disease control AVAILABLEThis program offers efgartigimod PH20 SC to adults with CIDP who cannot join clinical trials and have not been helped by existing treatments. The drug is injected under the skin and aims to control the disease. The program continues until the patient stops treatment or the drug b…
Matched conditions: CIDP
Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Body fat may change how well immune therapy works
Knowledge-focused Recruiting nowThis study looks at how a person's body composition (fat and muscle) affects the way immunoglobulin G (IgG) moves through the body after being given through a vein or under the skin. Researchers will enroll 20 adults with a nerve condition called CIDP who already receive IgG ther…
Matched conditions: CIDP
Phase: PHASE1 • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC